Medindia

X

Legal Options Are Being Evaluated By Glenmark After Its Diabetes Drug Setback

by Reshma Anand on  October 10, 2015 at 4:57 PM Corporate News   - G J E 4
Drug firm Glenmark Pharmaceuticals is evaluating legal options after the Delhi High Court restrained it from manufacturing and selling generic version of MSD's anti-diabetes medicines Januvia and Janumet.
Legal Options Are Being Evaluated By Glenmark After Its Diabetes Drug Setback
Legal Options Are Being Evaluated By Glenmark After Its Diabetes Drug Setback
Advertisement

"Glenmark accepts the Honorable High Court's decision. However the decision can be appealed and Glenmark is evaluating the possible legal options," the company said.

Advertisement
As per the High Court's Order, "Glenmark has been restrained by a decree of permanent injunction from making, using, selling, distributing, advertising, exporting, offering for sale or dealing in Sitagliptin Phosphate Monohydrate or any other salt of Sitagliptin in any form, alone or in combination with one or more other drugs".

Pharma major MerckSharp and Dohme (MSD) in its plea had sought injunction against Glenmark alleging that the Indian pharma company had violated its IPR over its anti-diabetes medicines, Januvia and Janumet, by coming out with their own drugs containing the same salts.

Source: PTI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All